CLODERM (clocortolone pivalate) by Enterprise Therapeutics is clinical pharmacology topical corticosteroids share anti-inflammatory, antipruritic and vasoconstrictive actions. First approved in 1977.
Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
CLODERM (clocortolone pivalate) is a topical corticosteroid cream approved in 1977 for inflammatory and pruritic dermatologic conditions. It works through anti-inflammatory, antipruritic, and vasoconstrictive mechanisms that reduce skin inflammation and itching. The drug is absorbed through intact or compromised skin and metabolized hepatically, with excretion via kidneys and bile.
Product is in late-stage maturity with minimal Medicare spending ($31K in 2023), signaling a mature, small-team commercial operation focused on maintenance rather than growth.
CLINICAL PHARMACOLOGY Topical corticosteroids share anti-inflammatory, antipruritic and vasoconstrictive actions. The mechanism of anti-inflammatory activity of the topical corticosteroids is unclear. Various laboratory methods, including vasoconstrictor assays, are used to compare and predict…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Worked on CLODERM at Enterprise Therapeutics? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
CLODERM currently shows zero linked job openings, reflecting its status as a mature, low-revenue product with minimal commercial expansion. Roles on this product are typically maintenance-oriented within small regional or specialty teams, offering limited visibility and advancement potential.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/mo